Skip to main content
Clinical Trials/NCT03148717
NCT03148717
Completed
Phase 2

Preoperative vs. Postoperative Rectal Misoprostol in Cesarean Section: A Randomized, Double Blind Clinical Trial

Ain Shams University1 site in 1 country300 target enrollmentMay 10, 2017

Overview

Phase
Phase 2
Intervention
Misoprostol
Conditions
Neonatal Outcome
Sponsor
Ain Shams University
Enrollment
300
Locations
1
Primary Endpoint
Neonatal outcome
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This prospective double-blind placebo-controlled randomized clinical trial will be conducted at Ain-Shams University Maternity Hospital from April 2017 till December 2017. Group 1 women, candidates for cesarean section, will receive preoperative rectal 400 microgram of misoprostol, and Group 2 women will receive postoperative rectal 400 microgram of misoprostol.

  1. 120 women candidate foe elective cesarean section will receive preoperative sublingual 400 microgram of misoprostol, and another 120 women will receive postoperative sublingual 400 microgram of misoprostol.
Registry
clinicaltrials.gov
Start Date
May 10, 2017
End Date
March 20, 2018
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mohamed S Sweed, MD

Assistant Professor

Ain Shams University

Eligibility Criteria

Inclusion Criteria

  • Patients candidate for cesarean section.
  • Full term pregnancies (GA 37- 42 Wks).
  • Age (18-40 yrs).
  • body mass index (BMI) (20-30(Kg/m2 .
  • Exclusion Criteia:
  • Contraindication to spinal anesthesia.
  • Blood dyscrasias.
  • Large fibroids.
  • Contraindications to prostaglandin therapy (e.g. history of severe bronchial asthma or allergy to misoprostol.
  • Emergency CS such as fetal distress

Exclusion Criteria

  • Not provided

Arms & Interventions

Preoperative

Group no.1 will receive preoperative rectal 400 microgram of misoprostol (Sigma) "2 tablets" and postoperative rectal placebo"2 tablets".

Intervention: Misoprostol

Preoperative

Group no.1 will receive preoperative rectal 400 microgram of misoprostol (Sigma) "2 tablets" and postoperative rectal placebo"2 tablets".

Intervention: Placebo

Postoperative

Group no.2 will receive preoperative rectal placebo "2 tablets" and postoperative rectal 400 microgram of misoprostol (Sigma) " 2 tablets" .

Intervention: Misoprostol

Postoperative

Group no.2 will receive preoperative rectal placebo "2 tablets" and postoperative rectal 400 microgram of misoprostol (Sigma) " 2 tablets" .

Intervention: Placebo

Outcomes

Primary Outcomes

Neonatal outcome

Time Frame: 5 minutes

measured by APGAR score at 5 minutes

Secondary Outcomes

  • NICU admission(24 hours)
  • amount of blood loss(24 hours)
  • Postpartum hemorrhage(24 hours)
  • Need for extra uterotonics(24 hours)

Study Sites (1)

Loading locations...

Similar Trials